Jane Street Group, LLC Beam Therapeutics Inc. Call Options Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$22.57 - $33.14 $1.37 Million - $2.01 Million	60,800 New	60,800 $1.49 Million
Q1 2022 May 17, 2022	BUY	$53.73 - $82.16 $1.95 Million - $2.98 Million	36,300 Added 453.75%	44,300 $2.54 Million
Q4 2021 Feb 15, 2022	SELL	$68.02 - $99.06 $714,210 - $1.04 Million	-10,500 Reduced 56.76%	8,000 $638,000
Q3 2021 Nov 16, 2021	SELL	$84.37 - $133.6 $4.18 Million - $6.63 Million	-49,600 Reduced 72.83%	18,500 $1.61 Million
Q2 2021 Aug 16, 2021	BUY	$64.12 - $128.71 $1.31 Million - $2.63 Million	20,400 Added 42.77%	68,100 $8.77 Million
Q1 2021 May 18, 2021	BUY	$71.28 - $120.75 $2.38 Million - $4.03 Million	33,400 Added 233.57%	47,700 $3.82 Million
Q4 2020 Feb 17, 2021	BUY	$22.24 - $95.63 $318,032 - $1.37 Million	14,300 New	14,300 $1.17 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $2.04B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.